Tag: GIP
Browse all articles tagged with “GIP”.
3 articles
Tirzepatide: The Dual GIP/GLP-1 Receptor Agonist Reshaping Metabolic Research
A comprehensive research overview of tirzepatide, the dual GIP/GLP-1 receptor agonist marketed as Mounjaro and Zepbound. Explore its mechanism, SURMOUNT and SURPASS trial data, $16.5B revenue trajectory, and how it compares to semaglutide.
Retatrutide: The Triple Agonist Setting New Records in Obesity Research
A research-focused overview of retatrutide (LY3437943), the investigational triple GIP/GLP-1/glucagon receptor agonist from Eli Lilly that achieved 23.7% body weight reduction in Phase 2 trials, the largest ever recorded in an obesity trial.
What Is Tirzepatide? A Research Overview
Tirzepatide is a dual GIP/GLP-1 receptor agonist that represents a new class of incretin-based therapeutics for type 2 diabetes and obesity management.
For informational purposes only. Not medical advice. Always consult with qualified healthcare professionals.